Suppression of local inflammation via galectin-anchored indoleamine 2,3-dioxygenase

Bracho‐Sanchez, Evelyn; Rocha, Fernanda Regina Godoy; Bedingfield, Sean K.; Partain, Brittany D.; Macias, Sabrina L.; Brusko, Todd M.; Colazo, Juan M.; Fettis, Margaret M.; Farhadi, Shaheen A.; Helm, Eric Y.; Koenders, Kevin; Kwiatkowski, Alexander J.; Restuccia, Antonietta; Morales, Bethsymarie Soto; Wanchoo, Arun; Avram, Dorina; Allen, Kyle D.; Duvall, Craig L.; Wallet, Shannon M.; Hudalla, Gregory A.; Keselowsky, Benjamin G.

doi:10.1038/s41551-023-01025-1

Cited by 13 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, the KYNU/IDO-TDO ratio demonstrated a significant increase in inflammatory diseases [ 25 ]. IDO promotes an anti-inflammatory environment in the skin by T-cell suppression and regulatory T-cell induction [ 50 ], which in turn reduces KYNU expression levels [ 25 ]. Therefore, this appears that inhibiting the IL-17 in an aptamer-treated group helps the modulation of an inflammatory milieu in the skin, thereby may affecting tryptophan metabolism through the IDO.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Kynu, Defb2, Camp, and Penk Expression Levels as Psoriasis Marker in the Imiquimod‐Induced Psoriasis Model

Emami,

Shobeiri,

Khorrami

et al. 2024

Mediators of Inflammation

View full text Add to dashboard Cite

Background. Psoriasis is a noncontagious auto‐inflammatory chronic skin disease. So far, some of the inflammatory genes were upregulated in mouse model of psoriasis. This study examined changes in skin mRNA expression of L‐kynureninase (Kynu), cathelicidin antimicrobial peptide (Camp), beta‐defensin 2 (Defb2), and proenkephalin (Penk) in a mouse model of imiquimod‐induced psoriasis. Materials and Methods. Tree groups of C57BL/6 female mice were allocated. The imiquimod (IMQ) cream was administered to the mice dorsal skin of the two groups to induce psoriatic inflammation. In the treatment group, IMQ was administered 10 min after hydrogel‐containing M7 anti‐IL‐17A aptamer treatment. Vaseline (Vas) was administered to the negative control group. The psoriatic skin lesions were evaluated based on the psoriasis area severity index (PASI) score, histopathology, and mRNA expression levels of Kynu, Camp, Defb2, and Penk using real‐time PCR. In order to assess the systemic response, the spleen and lymph node indexes were also evaluated. Results. The PASI and epidermal thickness scores were 6.01 and 1.96, respectively, in the IMQ group, and they significantly decreased after aptamer administration to 1.15 and 0.90, respectively (P < 0.05). Spleen and lymph node indexes showed an increase in the IMQ group, followed by a slight decrease after aptamer treatment (P > 0.05). Additionally, the mRNA expression levels of Kynu, Defb2, Camp, and Penk genes in the IMQ‐treated region showed a significant 2.70, 4.56, 3.29, and 2.61‐fold increase relative to the Vas mice, respectively (P < 0.05). The aptamer‐treated region exhibited a significant decrease in these gene expression levels (P < 0.05). A positive correlation was found between Kynu, Penk, and Camp expression levels and erythema, as well as Camp expression with PASI, scaling, and thickness (P < 0.05). Conclusion. According to our results, it seems that Kynu, Camp, and Penk can be considered appropriate markers for the evaluation of psoriasis in IMQ‐induced psoriasis. Also, the anti‐IL‐17 aptamer downregulated these important genes in this mouse model.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Kynu, Defb2, Camp, and Penk Expression Levels as Psoriasis Marker in the Imiquimod‐Induced Psoriasis Model

Emami,

Shobeiri,

Khorrami

et al. 2024

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…We conducted a series of preclinical evaluations using ABLE in the imiquimod (IMQ)–induced psoriasis model ( 31 ). This model is widely used in in vivo research because of its clinical and histological similarities to human psoriasis, including characteristic symptoms such as desquamation, thickening of the epithelial structure, skin inflammation, and dysregulated host skin microbiota ( 32 ).…”

Section: Skin Disease Monitoring and Therapy With Ableunclassified

Active biointegrated living electronics for managing inflammation

Shi,

Kim,

et al. 2024

Science

View full text Add to dashboard Cite

Seamless interfaces between electronic devices and biological tissues stand to revolutionize disease diagnosis and treatment. However, biological and biomechanical disparities between synthetic materials and living tissues present challenges at bioelectrical signal transduction interfaces. We introduce the active biointegrated living electronics (ABLE) platform, encompassing capabilities across the biogenic, biomechanical, and bioelectrical properties simultaneously. The living biointerface, comprising a bioelectronics layout and a Staphylococcus epidermidis –laden hydrogel composite, enables multimodal signal transduction at the microbial-mammalian nexus. The extracellular components of the living hydrogels, prepared through thermal release of naturally occurring amylose polymer chains, are viscoelastic, capable of sustaining the bacteria with high viability. Through electrophysiological recordings and wireless probing of skin electrical impedance, body temperature, and humidity, ABLE monitors microbial-driven intervention in psoriasis.

show abstract

“… 9 , 10 High expression of IDO can also disrupt the function of inflammatory cells and reduce the levels of inflammatory cytokines. 11 , 12 Our previous research identified significantly increased levels of the plasma and urine levels of IDO in patients with early-stage CKD, and that these levels were also associated with inflammation due to CKD. 13 , 14 Therefore, measurement of IDO activity along with other indicators may allow the timely and accurate prediction of early CKD and CKD progression.…”

Section: Introductionmentioning

confidence: 95%

Prediction Model for Early-Stage CKD Using the Naples Prognostic Score and Plasma Indoleamine 2,3-dioxygenase Activity

Hong,

Zheng,

Shi

et al. 2024

JIR

View full text Add to dashboard Cite

Purpose Changes in inflammation, immunity, and nutritional status can promote the development of chronic kidney disease (CKD), and the Naples prognostic score (NPS) reflects changes in these three general clinical parameters. Indoleamine 2.3-dioxygenase (IDO) can block the function of inflammatory cells and inhibit the production of inflammatory cytokines. We examined use of the NPS and IDO activity to predict early-stage CKD. Patients and Methods Clinical and demographic parameters and the NPS were recorded for 47 CKD patients and 30 healthy controls. A one-way ANOVA or the rank sum test was used to compare variables in the different groups. Spearman or Pearson correlation coefficients were calculated, and logistic regression was used to identify significant factors. Receiver operating characteristic (ROC) analysis was also performed. Results The NPS had a positive correlation with plasma IDO activity and IDO activity was lowest in controls, and increased with CKD stage. ROC analysis indicated that NPS had an area under the curve (AUC) of 0.779 when comparing controls with all CKD patients. A prediction model for CKD (−4.847 + [1.234 × NPS] + [6.160 × plasma IDO activity]) demonstrated significant differences between controls and patients with early-stage CKD, and for patients with different stages of CKD. This model had AUC values of 0.885 (control vs CKD1–4), 0.876 (control vs CKD2), 0.818 (CKD2 vs CKD3), and 0.758 (CKD3 vs CKD4). Conclusion A prediction model based on the NPS and IDO provided good to excellent predictions of early-stage CKD.

show abstract

Suppression of local inflammation via galectin-anchored indoleamine 2,3-dioxygenase

Cited by 13 publications

References 41 publications

Evaluation of Kynu, Defb2, Camp, and Penk Expression Levels as Psoriasis Marker in the Imiquimod‐Induced Psoriasis Model

Evaluation of Kynu, Defb2, Camp, and Penk Expression Levels as Psoriasis Marker in the Imiquimod‐Induced Psoriasis Model

Active biointegrated living electronics for managing inflammation

Prediction Model for Early-Stage CKD Using the Naples Prognostic Score and Plasma Indoleamine 2,3-dioxygenase Activity

Contact Info

Product

Resources

About